Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01965600 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01965600 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT01965600, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
An endotoxin challenge will be administered to healthy subjects to induce production of inflammatory markers. An investigational drug or placebo will be administered prior to the endotoxin challenge to assess the effect of the investigational drug on the markers of inflammation. Safety and tolerability will also be assessed.
Interventions
- DRUG Placebo
- DRUG PF-06282999
- OTHER LPS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01965600
The ClinicalTrials.gov registry entry for NCT01965600 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01965600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01965600 about?
NCT01965600 is a clinical study titled "A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model". An endotoxin challenge will be administered to healthy subjects to induce production of inflammatory markers. An investigational drug or placebo will be administered prior to the endotoxin challenge to assess the effect of the investigational drug on the markers of inflammation. Safety and tolerabil...
What is the current status of trial NCT01965600?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2014-03. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01965600?
The interventions under investigation include: Placebo (DRUG), PF-06282999 (DRUG), LPS (OTHER).
Who is sponsoring clinical trial NCT01965600?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.